All In Biotech

Drug Trial Radar · NCT04617314

A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors

A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Effect of RC108-ADC For Injection in Subjects With c-Met Positive Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

Mar 10, 2021

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, pharmacokinetics, and effect of RC108-ADC for injeciton in subjects with c-Met positive advanced malignant solid tumors.

Conditions

  • Solid Tumor

Interventions

  • RC108Drug

    RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse eventsTime frame: From the day of ICF signment to 28 days after the day of the last treatment
  2. Maximum Tolerated dose of RC108Time frame: 21 days after first treatment.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College

    Beijing, Beijing Municipality, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.